title: Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
abstract: P2Y12 inhibitors constitute an essential part of the antithrombotic treatment, with proven clinical benefit in acute coronary syndromes and after percutaneous coronary interventions. Substantial evidence has emerged that, apart from their primary antiplatelet action, P2Y12 receptor inhibitors exhibit several off-target effects. In this review, we present the supporting evidence of P2Y12 inhibitors' pleiotropic actions, discuss their clinical implications and underscore the necessity for further research on this issue.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Moulias
authors.forename: Ioanna
authors.initials: I
authors.lastname: Xanthopoulou
authors.affiliation: Patras University Hospital, Department of Cardiology, 26500, Patras, Greece. dalex@med.upatras.gr.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Alexopoulos
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy; D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12